CVS Health (CVS)
(Delayed Data from NYSE)
$66.63 USD
-0.22 (-0.33%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $66.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.63 USD
-0.22 (-0.33%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $66.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
A Value D Growth C Momentum B VGM
Zacks News
Walgreens Boots (WBA) Stock Looks Like A Cheap, Solid Buy Right Now
by Benjamin Rains
Shares of Walgreens Boots Alliance (WBA) jumped roughly 1.6% Monday as investors continue to dive in after it posted impressive fiscal fourth-quarter results late last week. Looking ahead, the pharmaceutical giant looks poised for strong growth and WBA stock seems like it might be worth buying right now.
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CVS Health (CVS) Stock Moves -0.72%: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $78.92, marking a -0.72% move from the previous day.
Walgreens (WBA) Stock Sinks 1.7% Ahead of Q4 Earnings: What to Watch
by Benjamin Rains
Shares of Walgreens Boots Alliance (WBA) slipped 1.7% during regular trading hours Wednesday in a sign that investors might be a tad bit nervous about the pharmacy and cosmetic giant's Q4 earnings results Thursday.
The Zacks Analyst Blog Highlights: JPMorgan, American Express, FedEx, PepsiCo and CVS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, American Express, FedEx, PepsiCo and CVS
Top Research Reports for JPMorgan, American Express & FedEx
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), American Express (AXP) and FedEx (FDX).
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for FLQL
CVS Health's Aetna Deal Imminent, PBM Selling Season Strong
by Zacks Equity Research
CVS Health (CVS) is steadily approaching the Aetna deal wrap-up. Per the company, this significant buyout might alter the whole Healthcare landscape in the United States.
The Zacks Analyst Blog Highlights: Adobe, United Technologies, Lockheed Martin, CVS Health and Coca-Cola
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Adobe, United Technologies, Lockheed Martin, CVS Health and Coca-Cola
Should You Buy Walgreens Boots (WBA) Stock Ahead of Q4 Earnings?
by Benjamin Rains
Walgreens Boots Alliance (WBA) shares have surged 17% in the last three months to outpace the S&P 500's roughly 7% climb as fears that Amazon's (AMZN) pharmaceutical push would doom the pharmacy giant prove overblown. Now the question is should investors consider buying WBA stock ahead of its Q4 earnings release on October 11?
Top Research Reports for Adobe, United Technologies & Lockheed Martin
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Adobe (ADBE), United Technologies (UTX) and Lockheed Martin (LMT).
Here's Why You Should Invest in CVS Health (CVS) Stock Now
by Zacks Equity Research
CVS Health's (CVS) solid cash position is encouraging. Strong 2019 PBM selling season is another upside.
Is CVS Health (CVS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cigna Gets Merger Nod, Forms Management for Unified Entity
by Zacks Equity Research
Cigna (CI) forms management as it prepares for new merged entity.
WellCare Health's (WCG) Buyout to Expand Medicare Business
by Zacks Equity Research
WellCare Health's (WCG) impending buyout of Aetna's Medicare business to expand and cement its foothold in the rapidly growing market.
Aetna a Step Closer to CVS Merger, Sells Medicare Business
by Zacks Equity Research
Aetna (AET) gets a step closer to its merger with CVS Health by selling its Medicare business to WellCare Health.
Are M&As Helping U.S. Markets Amid Trade War Fears?
by Ritujay Ghosh
This year so far has already seen quite a few big acquisitions, which is helping the broader market.
3 MedTech Stocks for Safe Returns as Hurricane Fears Peak
by Sweta Jaiswal
With the hurricane season at the peak, we bring three safe picks for investors.
Cigna Moves Closer to Express Scripts Buyout With DoJ Nod
by Zacks Equity Research
Cigna (CI) clears a significant regulatory hurdle with regards to its proposed acquisition of Express Scripts.
CVS Health (CVS) PBM Strengthens, Aetna Deal Shows Promise
by Zacks Equity Research
A robust 2019 PBM selling season is a tailwind for CVS Health (CVS). Additionally, the company's milestone acquisition of Aetna might alter the whole healthcare landscape in the United States.
The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder
Top Stock Reports for JPMorgan, Mastercard & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Mastercard (MA) and AbbVie (ABBV).
CVS Health (CVS) Up 10.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medical Services Boom Drives Healthcare: 3 Top Picks
by Sreyoshi Mukherjee
Considering the rising popularity of PBM, CRO and EHR in the U.S. Medical Services industry, these three picks might be money-spinning choices for investors.
CVS Health (CVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $74.08, moving +0.58% from the previous trading session.